Fig. 3: Efficacy of combination therapy with NK-92/5.28.z cells and anti-PD-1 antibody in orthotopic tumors.
From: CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma
a Schematic of the treatment regimen for tumor-bearing mice. b Representative MRI images taken on days 7 and 28 after tumor cell injection. c Relative tumor growth over time measured via MRI. d Kaplan–Meier survival analysis of all treatment cohorts after therapy of advanced tumors (n = 5, Log-Rank (Mantel–Cox) test, p = 0.0640). e Kaplan–Meier survival analysis of combination therapy of NK-92/5.28.z and anti-PD-1 compared to NK-92/5.28.z with control IgG after treatment of large late-stage tumors (n = 8–12, Log-Rank (Mantel–Cox) test, p = 0.0476).
